Halley E. Gilbert
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
Transaction History
| PCVX | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 | View on chart |
| ARQT | ▲ Buy | Grant | 5,778 | $0 | 6/5/2026 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 12,220 | $92K | 11/20/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 16,532 | $455K | 11/20/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 7,609 | $0 | 6/12/2025 | View on chart |
| PCVX | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 10,139 | $0 | 6/14/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 1,550 | $0 | 6/6/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 18,200 | $97K | 6/3/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 18,200 | $1.3M | 6/3/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 2,500 | $0 | 6/13/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,375 | $0 | 5/31/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,312 | $0 | 6/1/2022 | View on chart |
| PCVX | ▲ Buy | Grant | 3,125 | $0 | 6/1/2022 | View on chart |
| NEO | ▲ Buy | Grant | 42,036 | $0 | 3/1/2022 | View on chart |
| NEO | ▲ Buy | Grant | 45,858 | $0 | 12/30/2021 | View on chart |
| NEO | ▲ Buy | Grant | 59,228 | $0 | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.